CAB Spotlight - Vijaya Jori | Johns Hopkins University Baltimore-India Clinical Trials Unit

CAB Spotlight - Vijaya Jori

Date: 04/01/2022

Community Advisory Boards are key members of research programs. The ACTG Newsletter features Vijaya Jori of the JHU-BJGMC CAB!

1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

The study is being done to: test a strategy of using a resistance test to choose anti-HIV drugs. Resistance tests look at the...

Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...